ABL Bio Receives 91 Billion KRW Upfront Payment for Parkinson's Disease New Drug Technology Transfer Contract

[Asia Economy Reporter Lee Gwan-ju] ABL Bio announced on the 22nd that it has received a $75 million upfront payment (approximately 91 billion KRW) from Sanofi for the licensing of the bispecific antibody candidate 'ABL301' for the treatment of degenerative brain diseases such as Parkinson's disease.

Earlier in January, ABL Bio signed a joint development and licensing agreement with Sanofi worth a total of $1.06 billion, including the $75 million upfront payment and $45 million in short-term milestone payments.

ABL301 applies the 'Grabody-B' platform technology, which maximizes blood-brain barrier (BBB) penetration of therapeutic candidates for various central nervous system (CNS) diseases. It effectively delivers antibodies that inhibit the accumulation of alpha-synuclein, the cause of Parkinson's disease, into the brain, thereby enhancing therapeutic effects.

Lee Sang-hoon, CEO of ABL Bio, said, "The partnership between the two companies for innovative drug development has officially begun," adding, "Preclinical studies for ABL301's entry into clinical trials in the U.S. are progressing smoothly, and going forward, ABL Bio will continue to contribute to improving patients' lives through the development of various degenerative brain disease treatments applying the Grabody-B platform."

This content was produced with the assistance of AI translation services.